Suneel Katragadda, MD
Child & Adolescent Psychiatry · Atlanta, GANPI 1972632388
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $351,381 of the $459,890 with a category attached, or 76.4%. 26 manufacturers reported payments, led by Neurocrine Biosciences, Inc. at 34.6% of the total. 2025 is the largest year on record at $166,402, more than ten times the $10,527 reported in 2019. Among child & adolescent psychiatry clinicians in GA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 835 payments — averaging $550.77 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Neurocrine Biosciences, Inc.$159K
- Johnson & Johnson$86K
- Otsuka America Pharmaceutical, Inc.$72K
- Alkermes, Inc.$56K
- Axsome Therapeutics, Inc.$42K
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$24K
- plus $21K from 20 others
Across 411 payments — averaging $3902.62 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Janssen Research & Development, LLC$779K
- AbbVie$394K
- Otsuka Pharmaceutical Development & Commercialization, Inc.$260K
- Neurocrine Biosciences, Inc.$73K
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$31K
- Sumitomo Pharma America, Inc.$23K
- plus $44K from 5 others
What the payments were for
- Consulting fees$48,57111%
- Speaking & faculty fees$351,38176%
- Travel & lodging$35,6128%
- Food & beverage$24,2905%
- Education$360%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Neurocrine Biosciences, Inc. | 169 | $159,288 |
| Johnson & Johnson | 159 | $86,222 |
| Otsuka America Pharmaceutical, Inc. | 105 | $71,743 |
| Alkermes, Inc. | 89 | $55,601 |
| Axsome Therapeutics, Inc. | 42 | $42,068 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 39 | $24,290 |
| E.r. Squibb & Sons, L.L.C. | 15 | $9,607 |
| Ironshore Pharmaceuticals Inc. | 9 | $4,451 |
| AbbVie(2 entities) | 52 | $1,268 |
| Pfizer | 3 | $1,062 |
| Janssen Research & Development, LLC | 5 | $875 |
| Teva Pharmaceuticals USA, Inc. | 24 | $826 |
| Lundbeck LLC | 32 | $505 |
| Takeda Pharmaceuticals U.S.A., Inc. | 20 | $351 |
| Sunovion Pharmaceuticals Inc. | 20 | $299 |
| Tris Pharma Inc | 5 | $290 |
| Corium, LLC | 10 | $266 |
| Idorsia Pharmaceuticals US Inc | 10 | $196 |
| Supernus Pharmaceuticals, Inc. | 6 | $126 |
| Eisai Inc. | 1 | $115 |
| Noven Pharmaceuticals, Inc. | 1 | $114 |
| Shire North American Group Inc | 9 | $114 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 3 | $98 |
| Vanda Pharmaceuticals Inc. | 3 | $50 |
| Neos Therapeutics, LP | 2 | $33 |
| Noven Therapeutics, LLC | 2 | $30 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- LYBALVI$214,432
- INGREZZA$155,083
- SPRAVATO$81,363
- REXULTI$70,548
- Auvelity$41,150
- CAPLYTA$23,674
- COBENFY$7,231
- Jornay PM 20mg capsules (Bottle of 100)$4,179
- INVEGA SUSTENNA$3,018
- GEODON$1,062
- ARISTADA$956
- INVEGA TRINZA$886
- VRAYLAR$367
- ARISTADA INITIO$239
- Dyanavel XR$236
- Quillivant$236
- Quillichew ER$236
- Austedo XR$224
- UZEDY$128
- Leqembi$115
How this compares
$459,890 in reported general payments places this provider in the 95th percentile of 91 child & adolescent psychiatry providers in Georgia.
See all child & adolescent psychiatry providers in Georgia →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| SpravatoEsketamine Hcl | 13 | $32,113 |
| RexultiBrexpiprazole | 17 | $24,396 |
| VraylarCariprazine Hcl | 14 | $19,298 |
| Effexor XrVenlafaxine Hcl | 26 | $15,305 |
| TrintellixVortioxetine Hydrobromide | 23 | $11,292 |
| QuviviqDaridorexant Hcl | 14 | $5,179 |
| Lurasidone Hcl | 13 | $3,677 |
| Aripiprazole | 49 | $2,336 |
| Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine | 38 | $1,342 |
| Desvenlafaxine Succinate ErDesvenlafaxine Succinate | 19 | $715 |
| Buspirone Hcl | 65 | $663 |
| Ziprasidone Hcl | 14 | $603 |
| Olanzapine OdtOlanzapine | 13 | $531 |
| Venlafaxine Hcl ErVenlafaxine Hcl | 52 | $473 |
| Eszopiclone | 15 | $365 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonSpravato | $86,222 | $32,11313 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $71,743 | $24,39617 claims |
| AbbVieVraylar | $1,268 | $19,29814 claims |
| PfizerEffexor Xr | $1,062 | $15,30526 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix | $351 | $11,29223 claims |
| Idorsia Pharmaceuticals US IncQuviviq | $196 | $5,17914 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 91 child & adolescent psychiatry providers in Georgia.
Other child & adolescent psychiatry in Atlanta
- Olujimi AdefisanAtlanta$14K
- Mhd AlkhatibAtlanta$7K
- Mary HuberAtlanta$7K
- Douglas ChanAtlanta$4K
- Jane LanierAtlanta$3K
- Satyanarayana GedelaAtlanta$3K
- Ericka GoodwinAtlanta$1K
- Kerry SheahanAtlanta$1K
- Debora JohnsonAtlanta$695
- Melanie PointerAtlanta$669
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.